Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales
Question
Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales
Direct answer
A $5.5 billion upward revision to full-year net revenue lifts forward EPS consensus for LLY, supporting high-multiple mega-cap healthcare index weights. — bullish pressure on LLY via upward revisions to forward consensus revenue and operating cash flow.
- Original publisher
- Market Ontology
- Evidence through
- 2026-11-08
- Published
- 2026-11-08
- Revision
- 1 · 2026-11-08
Cite as: Market Ontology, “Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales”, revision 1, evidence through 2026-11-08. https://marketontology.com/catalysts/2026-11-08/eli-lilly-raised-2026-revenue-guidance-by-5-5b-to-91b-92b-on-glp-1-sales-ebdb65
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–4 weeks | upward revisions to forward consensus revenue and operating cash flow | 88 |
Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales
A $5.5 billion upward revision to full-year net revenue lifts forward EPS consensus for LLY, supporting high-multiple mega-cap healthcare index weights. — bullish pressure on LLY via upward revisions to forward consensus revenue and operating cash flow.
Company raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
- SourceCompany raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
- TransmissionA $5.5 billion upward revision to full-year net revenue lifts forward EPS consensus for LLY, supporting high-multiple mega-cap healthcare index weights.
- SummaryEli Lilly increased 2026 revenue guidance by $5.5 billion to $91-$92 billion. Growth reflects sustained adoption of obesity and diabetes therapies Mounjaro and Zepbound. The stock trades at 47 times earnings following a 57% rally.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-11-08Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales RiseLLY NVO
- 2026-11-08Novo Nordisk jumped 6% after oral weight-loss pill generated $810M in Q3LLY NVO
- 2026-11-08Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 DemandLLY NVO
- 2026-11-08Novo Nordisk and Lilly keep GLP-1 growth in focusIBB LLY NVO
- 2026-11-08Novo Nordisk and Lilly keep GLP-1 growth in focusLLY NVO
- 2026-11-08Eli Lilly Lifts Revenue Forecast by $5.5B as Novo Oral GLP-1 Sales RiseLLY NVO
- 2026-11-08Novo Nordisk raises full-year guidance after strong Q3LLY NVO
- 2026-11-08Novo Nordisk Lifts Full-Year Outlook as Oral Weight-Loss Pill Reaches $810MLLY NVO
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.